Clinical Trials AI
C

ConcertAI

ConcertAI's Accelerated Clinical Trials platform helps pharmaceutical sponsors and contract research organizations design, plan and run oncology studies. Built on CARAai, the company's agentic AI platform, it deploys assistants and agents for literature review, protocol design, feasibility analysis, site selection, competitive trial assessment and patient matching. Study teams translate inclusion and exclusion criteria into candidate cohorts, compare designs, estimate how a protocol change would affect recruitment, rank sites by the populations they serve and watch for signals such as slowing enrollment or rising screen failures, with the evidence behind each recommendation open for inspection. The platform connects with a sponsor's own data and trial systems.

ACT draws on Precision360, an oncology dataset refreshed weekly from a CancerLinQ network of more than 13 million deidentified records spanning solid tumors and hematologic cancers, with CARAai extracting stage, treatment history and response from clinical notes. ConcertAI launched it at SCOPE in February 2026 and says it can shorten trial timelines by 10 to 20 months.

The company, founded in 2018 and led by chief executive Eron Kelly, is based in Cambridge, Massachusetts, with offices in Bangalore, Frankfurt, Philadelphia and Tokyo. It counts 75% of the top 30 life sciences companies as clients across its products, among them AbbVie, AstraZeneca, Amgen, Merck and Regeneron, and AbbVie and Bristol Myers Squibb used its earlier digital trial tools. It also sells CancerLinQ to oncology practices and TeraRecon imaging software. ACT is sold through an enterprise demo.

AI Health Index verifiedNovember 19, 2026
Compare ConcertAI with other vendors
Founded
2018
Headquarters
Cambridge, Massachusetts
Categories
clinical-trials-ai
Indexed Products
Accelerated Clinical Trials, CARAai, Precision360, Study Design Assistant
Buyer Segments
Pharmaceutical trial sponsors, Contract research organizations, Clinical development teams, Clinical operations teams
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
AA on AI CentralityThe artificial intelligence is the product. Remove the model and there is nothing left to sell.
Vendor Published

Accelerated Clinical Trials is an AI product from end to end. CARAai's agents read literature, translate eligibility criteria into candidate cohorts, compare protocol designs, forecast the probability of meeting enrollment, assess sites and competing trials and match patients, and monitoring agents watch live trials for changes that threaten recruitment.

The licensed data and a sponsor's operational information come from separate sources, and the models are what turn them into scenarios a study team can compare and question in natural language. Without those predictions there is no protocol simulation or feasibility forecast to sell, which makes the models the product rather than a feature on top of a data license.

BB on Autonomy and Oversight ModelThe oversight structure is described and one part is missing, commonly the threshold at which the system stops or what happens after it is wrong.
Vendor Published

Study teams set protocol criteria and compare alternatives before choosing a design. The Study Design Assistant can run on its own to generate recommendations, with the supporting evidence laid out in a separate workspace, and the platform surfaces trial risks for the sponsor to investigate. Published examples show analysts interpreting that evidence and choosing what to act on, so the structure is a recommendation with its basis open to review.

What is not described is a required approval for each recommendation, a threshold that routes an unreliable forecast to a person, or a way to override an automated alert once it reaches a connected trial operations system.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

CARAai is ConcertAI's proprietary agentic AI platform, trained on millions of human curated clinical records, and it extracts variables from oncology notes and combines them with structured data. The ACT launch says its assistants run on advanced reasoning models, and a 2024 collaboration with NVIDIA identified inference microservices and Llama 3. The trial platform layers its own study planning and operations functions on CARAai. That names the approach and some of the technology.

There is no production inventory of the models behind each function, no list of active foundation model versions and no release process for changing the model behind a sponsor's enrollment forecast or protocol simulation.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The trial software runs on the company's own CARAai engine and oncology data, with NVIDIA named for computing and inference technology and AWS as the infrastructure partner. The 2024 NVIDIA collaboration described tooling around Llama 3, which identifies part of the model layer without confirming which provider handles trial data in current production, or whether the reasoning models behind ACT's assistants are hosted by ConcertAI or called from an outside service. No list sets out the service providers in each data or model workflow, and no retention or training terms govern sponsor inputs processed beyond ConcertAI's own systems.

CC on Clinical and Operational EvidenceNamed customers, or vendor reported percentages with no method, denominator or reference standard. Scale of use is recorded here and is not treated as evidence of benefit.
Vendor Published

AbbVie and Bristol Myers Squibb are named as customers of the company's earlier digital trial products, and its data appears in more than 500 peer reviewed publications. For the 2026 Accelerated Clinical Trials platform, the company claims timelines shortened by 10 to 20 months and describes fewer protocol amendments and shorter stages in a white paper, without naming the sponsors, trials or case counts behind the figures.

The 3.3 times faster patient identification figure belongs to CancerLinQ's provider prescreening, a separate workflow. Named deployments and publications establish the earlier products and the data. How the current platform performs against a comparison group in live sponsor trials is not shown.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

The trial software draws on Precision360, a deidentified oncology dataset, and CARAai was trained on millions of curated clinical records, with a separate flow for a sponsor's own data. Extracted variables are checked for accuracy before the dataset refreshes. The website privacy policy gives retention principles for site visitors and contacts only.

How trial documents, prompts and extracted data are retained, how sponsor data is deidentified and whether sponsor inputs can train CARAai are not stated. Data checks are described, while no procedure covers an unsafe recommendation, such as an eligibility change that would exclude a population a trial needs.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

The trial product uses deidentified data from Precision360 and can work with operational and research data a sponsor supplies. The public privacy policy covers corporate sites and communications only, and nothing sets out the terms for protected information inside ACT or when the company acts as a business associate for it. CancerLinQ, the company's provider product, sits under its own arrangements with oncology practices.

For the trial platform there is no agreement, plan or authorization path under which a sponsor could submit identifiable patient information, and no statement that the platform is limited to deidentified data either.

DD on Security Certifications and Trust CenterControls are asserted with nothing independent behind them, or nothing is published. Read the note before concluding anything: this is the grade most often corrected on a second pass, because assurance material frequently sits on a parent domain or inside an old announcement rather than on the product pages.
Vendor Published

NVIDIA and AWS are named as technology partners powering what the company calls secure intelligence infrastructure, and the corporate privacy policy covers information collected through its sites. For the trial platform there is no independent audit of the company's security controls, no SOC 2 report or ISO certificate and no trust center where a sponsor can review infrastructure or model scope. Partner names identify the technology in use. They do not establish the boundaries or period of any examination of the trial service, which holds sponsors' unpublished protocol designs and trial performance data.

BB on FDA and Regulatory StatusThe pathway is stated and in progress, or a clearance is named without the vintage and scope a buyer needs to match it to the product on offer. A product outside device regulation also sits here when the vendor publishes what it is for and in what setting and the product on offer matches, or names another regime it works under, such as a registration outside the United States. A general clause saying the service is not medical advice does not reach this band.
Vendor Published

The marketed functions support protocol design, site selection, recruitment estimates, patient matching and trial monitoring for sponsors and contract research organizations, as clinical development operations. The software is not presented as a diagnostic device or a tool that prescribes treatment for an individual.

ConcertAI also sells imaging software through TeraRecon and point of care tools through CancerLinQ, and any authorization or clinical intended use attached to those products does not set a device status for trial planning and monitoring. The positioning of ACT matches what it does: it informs research decisions made by sponsors.

CC on AI Governance and Bias DisclosureResponsible artificial intelligence is committed to in policy language with no evaluation behind it. Most of the index sits here.
Vendor Published

The oncology data is curated with consistency checks, and simulations show sponsors who would be represented in a trial under different eligibility criteria, which lets a researcher compare design choices for diversity before enrollment opens. ConcertAI appears in Frost and Sullivan's 2026 Frost Radar for AI in clinical trials.

A diversity simulation assesses projected recruitment under a protocol; it does not test whether CARAai makes systematically different errors when extracting or classifying records for different patient groups. There is no independent audit of model behavior and no comparison of error or calibration rates across patient populations or oncology settings.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

The design workspace shows supporting evidence beside each recommendation, and study staff can compare alternative scenarios before committing to a protocol, which lets a reviewer investigate a result. The terms on the company site cover site materials and limit liability for that use. They do not set the remedy for a mistaken enrollment forecast or a protocol recommendation under a sponsor's software agreement. No commitment to correct predictions, accuracy guarantee or route for a trial participant to challenge an output is offered, even as the company claims timeline savings of 10 to 20 months.

Integration and Deployment
CC on EHR and Interoperability DepthIntegration is claimed through standards or a middleware layer with no system named and nothing to verify.
Vendor Published

Accelerated Clinical Trials combines a sponsor's operational information with licensed oncology data in one workspace, and the company describes two way connections with trial and enterprise systems and CancerLinQ as the source for Precision360. No named EHR integration shows bidirectional exchange in a sponsor deployment.

CancerLinQ itself draws data from most major EHR systems on the provider side and runs its own embedded workflow, but those connections do not establish how ACT reads or updates clinical records. The integration story for ACT is about design and operational data moving across trial systems.

CC on Deployment Model and Data ResidencyA single hosted option with location implied rather than committed.
Vendor Published

ACT is sold as enterprise software that works with a sponsor's internal data and systems, and the company describes cloud and computing relationships with AWS and NVIDIA. Offices in Cambridge, Bangalore, Frankfurt, Philadelphia and Tokyo point to an international operation. Where sponsor materials are stored, whether model processing stays in one jurisdiction and where trial operational data is kept are not stated. The site privacy policy refers to international handling of site and communications data only. No deployment option, residency commitment or tenant boundary is described for a trial contract.

Commercial
DD on Commercial TransparencyNothing a buyer can establish before a sales conversation. A published pricing claim contradicted by evidence also grades here.
Vendor Published

Accelerated Clinical Trials is sold through a demo to sponsors and contract research organizations, with enterprise configuration across therapeutic areas and integration with operational systems. License tiers, the study or trial unit used for billing, data access prices and fees for connecting a sponsor's systems are not given.

Customer announcements describe collaborations and scope without contract amounts for the current software, and the 10 to 20 month timeline claim frames value without a price. A new sponsor cannot tell before a sales conversation how its study volume or data selection would change the charge.

CC on Setting and Specialty CoverageCoverage is claimed broadly without specifics, or stated clearly with nothing validating it yet.
Vendor Published

The platform is built for sponsor and contract research teams running clinical studies, with oncology at its center: solid tumors and hematologic cancers drawn from longitudinal records for feasibility and cohort scenarios. Enterprise configuration is offered across therapeutic areas, and the company's clients include 75% of the top 30 life sciences companies across its products. Earlier sponsor deployments used different trial software from the same company.

Nothing validates the current platform across named cancer subtypes or other indications, and data coverage does not establish accurate recruitment prediction for a given hospital, research network or site type.

Alternatives

Alternatives to ConcertAI

Other products that do the same kind of work as ConcertAI, and what each one does.

CancerLinQ is ConcertAI’s oncology software for practices, cancer centers and health system oncology programs. It turns longitudinal records into care quality measures, treatment context and clinical trial matches.

PhaseV provides clinical development software for pharmaceutical sponsors, biotechnology companies and contract research organizations, from offices in the Boston area and Tel Aviv, and says more than 40 biopharma companies and CROs use it.

Clinical trial platform that embeds patient identification, eSource and data capture inside provider organizations so trials can run in routine care, paired with its own recruitment coordinators and eligibility specialists.

HealthKey helps research practices find potential clinical trial participants in their existing patient records. Teams supply a protocol's inclusion and exclusion criteria, and the software applies those criteria across structured EHR fields, clinical notes, and documents such as faxed PDFs.

IQVIA, based in Research Triangle Park, North Carolina, sells clinical research services, health data and technology to life sciences companies.

OM1 is a Boston real world data and AI company that Richard Gliklich, a physician, founded in 2015. It sells to drug and diagnostics makers, health systems and payers, and the companies it names include Amgen, AbbVie, GSK, Johnson & Johnson, Hologic and Exact Sciences.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Contact for enterprise pricing
Enterprise sale through a demo, configured by therapeutic area and integration scope. No business associate role or agreement is stated for the trial platform. No integration or configuration fee is listed. Vendor Published

ConcertAI markets Accelerated Clinical Trials to sponsors and contract research organizations. License prices, a billing unit and fees for connecting sponsor systems are not listed.